Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sang Hee Cho

Showing results (121-130 of 147) with videos related to

Pageof 15
Sort By:
Journal of Gastric Cancer|October 11, 2019
Exosomal miR-181b-5p Downregulation in Ascites Serves as a Potential Diagnostic Biomarker for Gastric Cancer-associated Malignant AscitesJieun Yun, Sang-Bae Han, Hong Jun Kim, et al.
Cancer Chemotherapy and Pharmacology|August 29, 2012
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02Yoon Hee Choi, Sang Cheul Oh, Jun Suk Kim, et al.
Journal of Korean Medical Science|June 17, 2006
A case of non-functioning huge adrenocortical carcinoma extending into inferior vena cava and right atriumKye Hun Kim, Jong Chun Park, Sang Yup Lim, et al.
Oncology Letters|June 23, 2020
Comparison of long-term treatment outcomes of T2N0M0 laryngeal squamous cell carcinoma using different treatment methodsEun Kyung Jung, Seong-Min Jin, Jae-Gu Kim, et al.
Cancer Investigation|February 6, 2026
Predictive and Prognostic Value of p16 in Head and Neck Squamous Cell Carcinoma Patients Treated with Molecular Targeted Agents or Immune Checkpoint Inhibitors: Subgroup Analysis of the TRIUMPH StudyHyerim Ha, Sang Hoon Chun, Yun-Gyoo Lee, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 30, 2020
Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)Keun-Wook Lee, Ik-Joo Chung, Min-Hee Ryu, et al.
Journal of Cancer|September 15, 2015
A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal CancerJung Han Kim, Dae Young Zang, Ik-Joo Chung, et al.
Cancer Research and Treatment|December 8, 2023
A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal CancerKeun-Wook Lee, Sae-Won Han, Tae Won Kim, et al.
BMC Cancer|November 9, 2014
Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV statusMin-Jee Kim, Myung-Seo Ki, Karham Kim, et al.
The Lancet. Oncology|March 21, 2018
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trialRui-Hua Xu, Kei Muro, Satoshi Morita, et al.
Pageof 15

Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
Journal of Gastric Cancer|October 11, 2019
Exosomal miR-181b-5p Downregulation in Ascites Serves as a Potential Diagnostic Biomarker for Gastric Cancer-associated Malignant AscitesJieun Yun, Sang-Bae Han, Hong Jun Kim, et al.
Cancer Chemotherapy and Pharmacology|August 29, 2012
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02Yoon Hee Choi, Sang Cheul Oh, Jun Suk Kim, et al.
Journal of Korean Medical Science|June 17, 2006
A case of non-functioning huge adrenocortical carcinoma extending into inferior vena cava and right atriumKye Hun Kim, Jong Chun Park, Sang Yup Lim, et al.
Oncology Letters|June 23, 2020
Comparison of long-term treatment outcomes of T2N0M0 laryngeal squamous cell carcinoma using different treatment methodsEun Kyung Jung, Seong-Min Jin, Jae-Gu Kim, et al.
Cancer Investigation|February 6, 2026
Predictive and Prognostic Value of p16 in Head and Neck Squamous Cell Carcinoma Patients Treated with Molecular Targeted Agents or Immune Checkpoint Inhibitors: Subgroup Analysis of the TRIUMPH StudyHyerim Ha, Sang Hoon Chun, Yun-Gyoo Lee, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 30, 2020
Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)Keun-Wook Lee, Ik-Joo Chung, Min-Hee Ryu, et al.
Journal of Cancer|September 15, 2015
A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal CancerJung Han Kim, Dae Young Zang, Ik-Joo Chung, et al.
Cancer Research and Treatment|December 8, 2023
A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal CancerKeun-Wook Lee, Sae-Won Han, Tae Won Kim, et al.
BMC Cancer|November 9, 2014
Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV statusMin-Jee Kim, Myung-Seo Ki, Karham Kim, et al.
The Lancet. Oncology|March 21, 2018
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trialRui-Hua Xu, Kei Muro, Satoshi Morita, et al.
Pageof 15